Novartis’ Itvisma (onasemnogene) has been approved by the US FDA to treat spinal muscular atrophy (SMA) in children aged two ...

Regeneron Pharmaceuticals’ Libtayo (cemiplimab) has received approval from the European Commission for the adjuvant treatment ...

Overall, ESMO 2025 reinforced the growing potential of biomarkers in cancer, with AI integration accelerating adoption. As ...

Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research ...

As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector ...

Tonix Pharmaceuticals has launched Tonmya (cyclobenzaprine), a newly approved oral treatment for adults with fibromyalgia.

SQD, an innovative recruitment and retention success scoring tool that helps clinical trial sponsors predict, measure, and ...

Markets and regulators will keep shifting, but an agile medical affairs function, built on flexible resourcing and ...

Over the past six decades, anti-thrombotic drug therapies have undergone a revolution, leading to major improvements in ...

Can you believe there are still outdated myths about the strategic value Medical Affairs (MA) brings to the table? There’s ...

Systematic literature reviews (SLRs) are a resource heavy, time-consuming but necessary part of evidence generation. SLRs present an opportunity for artificial intelligence (AI) to deliver significant ...

Johnson & Johnson (J&J) has announced new data showing that Tremfya (guselkumab) reduces symptoms of psoriatic arthritis (PsA ...